Last reviewed · How we verify

ZuraPrep without 70% IPA

Zurex Pharma, Inc. · Phase 3 active Small molecule ✓ Verified May 2026

ZuraPrep without 70% IPA is a Topical antiseptic Small molecule drug developed by Zurex Pharma, Inc.. It is currently in Phase 3 development for Prevention of surgical site infections. Also known as: ZuraPrep Vehicle.

ZuraPrep without 70% IPA is a topical antiseptic solution that helps prevent surgical site infections by reducing microbial load.

ZuraPrep is a topical antimicrobial agent used for surgical skin preparation to reduce the risk of surgical site infections. It has been clinically evaluated for its efficacy in in-vivo studies, with results from the study "In-vivo Efficacy of Patient Preoperative Prep" (NCT02831998) indicating its effectiveness in this application.

Likelihood of approval
60.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
  • Anti-infectives pathway favourability +2.0pp
    Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameZuraPrep without 70% IPA
Also known asZuraPrep Vehicle
SponsorZurex Pharma, Inc.
Drug classTopical antiseptic
ModalitySmall molecule
Therapeutic areaSurgical site infection prevention
PhasePhase 3

Mechanism of action

It achieves this by denaturing proteins and disrupting cell membranes of microorganisms, thereby inhibiting their growth and replication. This mechanism is effective against a broad spectrum of bacteria, viruses, and fungi.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ZuraPrep without 70% IPA

What is ZuraPrep without 70% IPA?

ZuraPrep without 70% IPA is a Topical antiseptic drug developed by Zurex Pharma, Inc., indicated for Prevention of surgical site infections.

How does ZuraPrep without 70% IPA work?

ZuraPrep without 70% IPA is a topical antiseptic solution that helps prevent surgical site infections by reducing microbial load.

What is ZuraPrep without 70% IPA used for?

ZuraPrep without 70% IPA is indicated for Prevention of surgical site infections.

Who makes ZuraPrep without 70% IPA?

ZuraPrep without 70% IPA is developed by Zurex Pharma, Inc. (see full Zurex Pharma, Inc. pipeline at /company/zurex-pharma-inc).

Is ZuraPrep without 70% IPA also known as anything else?

ZuraPrep without 70% IPA is also known as ZuraPrep Vehicle.

What drug class is ZuraPrep without 70% IPA in?

ZuraPrep without 70% IPA belongs to the Topical antiseptic class. See all Topical antiseptic drugs at /class/topical-antiseptic.

What development phase is ZuraPrep without 70% IPA in?

ZuraPrep without 70% IPA is in Phase 3.

What are the side effects of ZuraPrep without 70% IPA?

Common side effects of ZuraPrep without 70% IPA include Skin irritation.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing